Mostrar el registro sencillo del ítem

dc.contributor.authorPeña Martín, María Celsa
dc.contributor.authorGarcía Berrocal, Belén
dc.contributor.authorSánchez Martín, Almudena
dc.contributor.authorMarcos Vadillo, Elena
dc.contributor.authorGarcía Salgado, María Jesús
dc.contributor.authorSánchez Iglesias, Santiago
dc.contributor.authorLorenzo, Carolina
dc.contributor.authorGonzález Parra, David
dc.contributor.authorSans, Francisco
dc.contributor.authorFranco Martín, Manuel Ángel
dc.contributor.authorGaedigk, Andrea
dc.contributor.authorMateos Sexmero, María José
dc.contributor.authorSanz Lozano, Catalina
dc.contributor.authorIsidoro García, María
dc.date.accessioned2023-11-15T08:39:20Z
dc.date.available2023-11-15T08:39:20Z
dc.date.issued2022
dc.identifier.citationPharmaceutics, 2022, Vol. 14, Nº. 1, 160es
dc.identifier.issn1999-4923es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/62969
dc.descriptionProducción Científicaes
dc.description.abstractPrecision medicine utilizing the genetic information of genes involved in the metabolism and disposition of drugs can not only improve drug efficacy but also prevent or minimize adverse events. Polypharmacy is common among multimorbid patients and is associated with increased adverse events. One of the main objectives in health care is safe and efficacious drug therapy, which is directly correlated to the individual response to treatment. Precision medicine can increase drug safety in many scenarios, including polypharmacy. In this report, we share our experience utilizing precision medicine over the past ten years. Based on our experience using pharmacogenetic (PGx)-informed prescribing, we implemented a five-step precision medicine protocol (5SPM) that includes the assessment of the biological–clinical characteristics of the patient, current and past prescription history, and the patient’s PGx test results. To illustrate our approach, we present cases highlighting the clinical relevance of precision medicine with a focus on patients with a complex history and polypharmacy.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherMDPIes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectPharmacogeneticses
dc.subjectFarmacogenéticaes
dc.subjectPolypharmacyes
dc.subjectPrecision medicinees
dc.subjectMedicina personalitzadaes
dc.subjectPharmacotherapyes
dc.subjectFarmacología - Terapéuticaes
dc.subjectPharmacology/Toxicologyes
dc.subjectGeneticses
dc.subjectGeneticaes
dc.subjectDrugs
dc.subjectMedicamentos
dc.titleTen years of experience support pharmacogenetic Testing to guide individualized drug therapyes
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holder© 2022 The Authorses
dc.identifier.doi10.3390/pharmaceutics14010160es
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/14/1/160es
dc.identifier.publicationfirstpage160es
dc.identifier.publicationissue1es
dc.identifier.publicationtitlePharmaceuticses
dc.identifier.publicationvolume14es
dc.peerreviewedSIes
dc.description.projectInstituto de Salud Carlos III y Fondo Europeo de Desarrollo Regional (FEDER) - (grant IMP/00009 y RD16/0006/0019)es
dc.identifier.essn1999-4923es
dc.rightsAtribución 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones
dc.subject.unesco32 Ciencias Médicases
dc.subject.unesco3209 Farmacologíaes
dc.subject.unesco3214 Toxicologíaes


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem